Should I get a comprehensive genomic panel for Follicular Lymphoma

Genomic Testing for Follicular Lymphoma: What You Should Know

This is an excellent question, and the answer depends on your specific situation. Let me explain what the evidence shows and what questions to discuss with your care team.

What Genomic Testing Can Show

According to the NCCN Guidelines for Follicular Lymphoma, genetic testing looks for specific mutations and chromosomal changes in your cancer cells (not your inherited genes). These tests can identify:

• BCL2 and BCL6 rearrangements - translocations (chromosome breaks and rearrangements) that are common in FL
• Mutations in genes like EZH2, TNFRSF14, and STAT6 - which may provide information about your disease
• 1p36 deletions and IRF4/MUM1 rearrangements - which help classify your specific type of FL

When Genomic Testing Is Recommended

According to NCCN Guidelines, comprehensive genomic testing is considered "useful under certain circumstances" rather than essential for all patients. This typically includes:

✅ More likely recommended if:

• Your diagnosis is unclear or atypical
• Your FL shows unusual features (like being CD10-negative or BCL2-negative)
• Your disease is progressing unusually
• Your care team is considering clinical trials
• You have grade 3A FL (where management is more controversial)

❌ May not be necessary if:

• You have classic FL with typical features (CD10+, BCL2+, CD20+)
• Your initial immunohistochemistry (IHC) and flow cytometry results are clear
• You're starting standard first-line treatment

The Clinical Reasoning

Doctors typically consider genomic testing when:

1. Diagnosis confirmation is needed - to rule out other lymphomas that look similar
2. Treatment selection - certain mutations may influence which therapies work best
3. Prognostic information - some mutations suggest more aggressive disease
4. Clinical trial eligibility - many trials require specific genetic profiles

Questions to Ask Your Oncologist

Since this decision is individualized, here are specific questions to discuss:

1. "Based on my biopsy results and immunophenotyping, do you recommend comprehensive genomic testing for my case?"

2. "What specific mutations or rearrangements would change my treatment plan?"

3. "Are there any clinical trials I might be eligible for that would require genomic testing?"

4. "If we don't do comprehensive testing now, could we do it later if my disease behaves unexpectedly?"

5. "What is the cost, and does my insurance typically cover this testing?"

Important Context

The NCCN Guidelines note that next-generation sequencing (NGS) panels including genes like CREBBP, EZH2, MAP2K1, TNFRSF14, and STAT6 are available and can provide useful information. However, the presence or absence of these mutations doesn't automatically change standard treatment recommendations for most patients with classic FL.

Your oncologist's experience and your specific clinical features matter more than any single genetic test result.

Bottom Line

Your oncologist will determine whether comprehensive genomic testing is appropriate for YOUR case based on:

• Your specific FL characteristics
• Whether your diagnosis is completely clear
• Your treatment plan
• Whether it might affect clinical trial eligibility
• Your preferences and values

This is not a decision you need to make alone—it's a conversation with your care team.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.